Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 300

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 300
---
 board of directors, will take into account the relevant available facts and circumstances including:

| • |     | the risks, costs, and benefits to us; |

| • |     | the impact on a director’s independence in the event the related person is a director, immediate family 
 member of a director or an entity with which a director is affiliated;                                  |

| • |     | the terms of the transaction; |

| • |     | the availability of other sources for comparable services or products; and |

| • |     | the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. |

The policy will require that, in determining whether to approve, ratify or reject a related person transaction, our audit committee, or other independent body of our board of directors, must consider, in light of known circumstances, whether the transaction is in, or is not inconsistent with, our best interests and those of our stockholders, as our audit committee, or other independent body of our board of directors, determines in the good faith exercise of its discretion. All of the transactions described in this section were entered into prior to the adoption of this policy. Although we have not had a written policy for the review and approval of transactions with related persons, our board of directors has historically reviewed and approved any transaction where a director or officer had a financial interest, including the transactions described above. Prior to approving such a transaction, the material 203

facts as to a director’s or officer’s relationship or interest in the agreement or transaction were disclosed to our board of directors. Our board of directors took this information
into account when evaluating the transaction and in determining whether such transaction was fair to us and in the best interest of all our stockholders.

204

PRINCIPAL STOCKHOLDERS The following table sets forth information regarding beneficial ownership of our capital stock as of by:

| • |     | each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock; |

| • |     | each of our directors; |

| • |     | each of our named executive officers; and |

| • |     | all of our current executive officers and directors as a group. |

The percentage ownership information shown in the table prior to this offering is based on shares of common stock outstanding as of (which includes shares of restricted common stock that remained unvested and subject to forfeiture as of such date), after giving effect to the automatic